Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2008-01-22
2008-01-22
O'Hara, Eileen B. (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C530S350000, C536S023100, C536S023400, C536S023500
Reexamination Certificate
active
07320796
ABSTRACT:
Novel TNF receptor polypeptides are disclosed, along with polynucleotides encoding the polypeptides and uses thereof.
REFERENCES:
patent: 5312733 (1994-05-01), MacLeod
patent: 5489743 (1996-02-01), Robinson et al.
patent: 5605690 (1997-02-01), Jacobs
patent: 5670319 (1997-09-01), Goeddel et al.
patent: 5843789 (1998-12-01), Nomura et al.
patent: 5863769 (1999-01-01), Young
patent: 5885800 (1999-03-01), Emery et al.
patent: 5942385 (1999-08-01), Hirth
patent: 6271366 (2001-08-01), Kimura et al.
patent: 6274339 (2001-08-01), Moore et al.
patent: 6346382 (2002-02-01), Summar et al.
patent: 6599716 (2003-07-01), Hsu
patent: 2003/0082736 (2003-05-01), Smith
patent: 2003/0096355 (2003-05-01), Zhang
patent: 19809978 (1999-09-01), None
patent: 0 648 783 (1995-04-01), None
patent: 0861850 (1998-09-01), None
patent: 93/19777 (1993-10-01), None
patent: 94/06476 (1994-03-01), None
patent: WO-96/14328 (1996-05-01), None
patent: WO-96/37609 (1996-11-01), None
patent: 98/35986 (1998-07-01), None
patent: WO-98/30694 (1998-07-01), None
patent: WO 98/43998 (1998-08-01), None
patent: 98/43998 (1998-10-01), None
patent: WO-9843998 (1998-10-01), None
patent: 99/03992 (1999-01-01), None
patent: WO-99/04001 (1999-01-01), None
patent: WO-99/06426 (1999-02-01), None
patent: WO-99/07738 (1999-02-01), None
patent: WO-99/14330 (1999-03-01), None
patent: WO-99/20758 (1999-05-01), None
patent: WO-99/23105 (1999-05-01), None
patent: WO-99/26977 (1999-06-01), None
patent: WO-99/35268 (1999-07-01), None
patent: WO-99/50413 (1999-10-01), None
patent: WO-99/51744 (1999-10-01), None
patent: WO-00/08139 (2000-02-01), None
patent: WO-00/18800 (2000-04-01), None
Skolnick et al., From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotechnology, pp. 34-39, 2000.
EST Database Accession No. A1747041, Jun. 22, 1999.
Locksley et al., The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology, Cell, 104:487-501(2001).
Moult, The Current State of the Art In Protein Structure Prediction, Curr. Op. in Biotech., 7(4):422-427(1996).
Nophar et al., Soluble Forms of Tumor Necrosis Factor Receptors (TNF-Rs). The cDNA for the Type I TNF-R, Cloned Using Amino Acid Sequence Data of its Soluble Form, Encodes Both the Cell Surface and a Soluble Form of the Receptor, EMBOJ., 9(10):3269-3278(1990).
Orlinick and Chao, TNF-Related Ligands and Their Receptors, Cell Signal, 10(8):543-551(1998).
Ouchterlony and Nilsson, Immunodiffusion and Immunoelectrophoresis in: Handbook of Experimental Immunology ed. D. Weir, Blackwell, 1973.
Porteu et al., Human Neutrophil Elastase Releases a Ligand-binding Fragment from the 75-kDa Tumor Necrosis Factor (TNF) Receptor, J. Biol. Chem., 266:18846-18853(1991).
Smith et al., Four New Members Expand the Interleukin-1 Superfamily, J. Bio. Chem., 275(2):1169-1175(2000).
Vaitukaitis et al., A Method For Producing Specific Antisera With Small Doses of Immunogen, J. Clin. Endocrinol., 33:988-991(1971).
Wallach et al., Soluble and Cell Surface Receptors for Tumor Necrosis Factor, Agents Actions Suppl., 35:51-57(1991).
Baker and Reddy, Transducers of Life and Death: TNF Receptor Superfamily and Associated Proteins, Oncogene, 12(1):1-9(1996).
Beyaert and Fiers, Tumor Necrosis Factor and Lymphokines in: Cytokines eds. Anthony Mire-Sluis and Robin Thorpe, Academic Press San Diego CA, 1998.
Browning et al., Lymphotoxin .beta., a Novel Member of the TNF Family That Forms a Heteromeric Complex with Lymphotoxin on the Cell Surface, Cell, 72:847-856, (1993).
Fernandez-Botran, Soluble Cytokine Receptors: Their Role In Immunoregulation, FASB J., 5:2567-2574(1991).
Fisher, Production of Antibody in Radioimmunoassay in; Manual of Clinical Immunology, 2d Ed. (Rose and Friedman, eds.) Amer. Soc. For Microbiol., Washington, D.C., 1980.
Genebank accension No. aa155701, “zo70e05.r1 Stratagene pancreas (#937208( )Homo sapienscDNA clone IMAGE:592256 5′, mRNA sequence”, Hillier et al., 1997.
Genbank accension No. AAC50332, TNF-related Apoptosis Inducing Ligand Trail, Wiley et al., Jan. 6, 1996.
Genbank accension No. NP033451, TNF-Related Apoptosis Inducing Ligand [Mus musculus], Wiley et al., 2000.
Genbank accension No. CAA26669, TNF-alpha [Homo sapiens], Nedwin et al., Feb. 17, 1997.
Genbank accension No. CAA68530, TNF-alpha [Mus musculus], Jongeneel, May 11, 1993.
Aderka et al., The Potential Biological and Chemical Significance of the Soluble Tumor Necrosis Factor Receptors, Cytokine & Growth Factor Reviews, 7(3):231-240(1996).
Aggarwal et al., Characterization of Receptors for Tumor Necrosis Factor and their Regulation By .gamma.-Interferon, Nature, 318:665-667(1985).
Ausubel et al., eds., Current Protocols in Molecular Biology, 1, Section 9.1.1-9.1.3, John Wiley & Sons, New York 1996.
Degli-Esposti et al., “Cloning and Characterization of TRAIL-R3, a Novel Member of the Emerging TRAIL Receptor Family”, The Rockefeller University Press, vol. 186.
Pan et al., “TRUDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling,” FEBS Letters 424, Jan. 12, 1998, pp. 41-45.
Delgli-Esposti, “To die or not to die—the quest of the TRAIL receptors”, Journal of Leukocyte Biology, vol. 65, May 1999, pp. 535-542.
Schneider et al., “Characterization of two receptors for TRAIL”, FEBS Letters 416, Sep. 24, 1997, pp. 329-334.
McFarlane et al., “Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL”, The Journal of Biological Chemistry, vol. 272, No. 41, July.
Meurs et al., “Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase”, Proc. Natl. Acad. Sci. USA, vol. 90, Jan. 1993, pp. 232-.
Walczak et al., “TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL”, The EMBO Journal, vol. 16, No. 17, 1997, pp. 5386-5397.
“KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene”, Nature Genetics, vol. 17, Oct. 1997, pp. 141-143.
Degli-Esposti, et al., “The Novel Receptor TRAIL-R4 Induces NF-kb and Protects against TRAIL-Mediated Apoptosis, yet Retains an Incomplete Death Domain”, Immunity, vol.
Naismith et al., “Modularity in the TNF-receptor family”, TIBS 23, Feb. 1998, pp. 74-79.
Hofmann, “The modular nature of apoptotic signaling proteins”, CMLS, vol. 55, 1999, pp. 1113-1128.
Marsters, et al., “A novel receptor for ApoL/TRAIL contains a truncated death domain”, Current Biology, vol. 7, No. 12, 1997, pp. 1003-1006.
Pitti, et al., “Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer”, Nature, vol. 396, Dec. 17, 1998, pp. 699-703.
Sheridan et al., “Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors”, Science, vol. 277, Aug. 8, 1997, pp. 818-821.
Simonet et al., “Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density”, Cell, vol. 89, Apr. 18, 1997, pp. 309-319.
Griffith et al., “TRAIL: a molecule with multiple receptors and control mechanisms”, pp. 559-563.
Emery et al., “Osteoprotegerin is a Receptor for the Cytotoxic Ligand TRAIL”, The Journal of Biological Chemistry, vol. 273, No. 23, Jun. 5, 1998, pp. 1463-1467.
Pan et al., “The Receptor for the Cytotoxic Ligand TRAIL”, Science, vol. 276, Apr. 4, 1997, pp. 111-113.
Pan et al., “An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL”, Science, vol. 277, Aug. 8, 1997, pp. 815-818.
Bucay et al., “osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification”, Genes & Development, vol. 12, 1998, pp. 1260-1268.
Wu et al., Molecular Cloning and Functional Analysis of the Mouse Homologue of the KILLER/DR5 Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death.
Griffith, et al., “Monocyte-mediated Tumoricidal Activity via the Tumor Necrosi
Amgen Inc.
Marshall & Gerstein & Borun LLP
O'Hara Eileen B.
LandOfFree
Isolation, identification and characterization of tmst2, a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolation, identification and characterization of tmst2, a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolation, identification and characterization of tmst2, a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2812686